Hide metadata

dc.date.accessioned2018-08-24T08:20:35Z
dc.date.available2019-05-19T22:46:58Z
dc.date.created2018-06-27T16:39:27Z
dc.date.issued2018
dc.identifier.citationBinde, Caroline Ditlev Tvete, Ingunn Fride Gåsemyr, Jørund Inge Natvig, Bent Klemp, Marianne . A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. British Journal of Clinical Pharmacology. 2018
dc.identifier.urihttp://hdl.handle.net/10852/63690
dc.description.abstractAims To the best of our knowledge, there are no systematic reviews or meta‐analyses that compare rasagiline, selegiline and safinamide. Therefore, we aimed to perform a drug class review comparing all available monoamine oxidase type B (MAO‐B) inhibitors in a multiple treatment comparison. Methods We performed a systematic literature search to identify randomized controlled trials assessing the efficacy of MAO‐B inhibitors in patients with Parkinson's disease. MAO‐B inhibitors were evaluated either as monotherapy or in combination with levodopa or dopamine agonists. Endpoints of interest were change in the Unified Parkinson's Disease Rating Scale (UPDRS) score and serious adverse events. We estimated the relative effect of each MAO‐B inhibitor versus the comparator drug by creating three networks of direct and indirect comparisons. For each of the networks, we considered a joint model. Results The systematic literature search and study selection process identified 27 publications eligible for our three network analyses. We found the relative effects of rasagiline, safinamide and selegiline treatment given alone and compared to placebo in a model without explanatory variables to be 1.560 (1.409, 1.734), 1.449 (0.873, 2.413) and 1.532 (1.337, 1.757) respectively. We also found all MAO‐B inhibitors to be efficient when given together with levodopa. When ranking the MAO‐B inhibitors given in combination with levodopa, selegiline was the most effective and rasagiline was the second best. Conclusions All of the included MAO‐B inhibitors were effective compared to placebo when given as monotherapy. Combination therapy with MAO‐B inhibitors and levodopa showed that all three MAO‐B inhibitors were effective compared to placebo, but selegiline was the most effective drug. This is the peer reviewed version of the, which has been published in final form by Wiley. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.en_US
dc.languageEN
dc.language.isoenen_US
dc.publisherBlackwell Scientific Publications
dc.titleA multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's diseaseen_US
dc.title.alternativeENEngelskEnglishA multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease
dc.typeJournal articleen_US
dc.creator.authorBinde, Caroline Ditlev
dc.creator.authorTvete, Ingunn Fride
dc.creator.authorGåsemyr, Jørund Inge
dc.creator.authorNatvig, Bent
dc.creator.authorKlemp, Marianne
cristin.unitcode185,53,18,15
cristin.unitnameAvdeling for farmakologi
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode2
dc.identifier.cristin1594292
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British Journal of Clinical Pharmacology&rft.volume=&rft.spage=&rft.date=2018
dc.identifier.jtitleBritish Journal of Clinical Pharmacology
dc.identifier.volume84
dc.identifier.issue9
dc.identifier.startpage1917
dc.identifier.endpage1927
dc.identifier.doihttp://dx.doi.org/10.1111/bcp.13651
dc.identifier.urnURN:NBN:no-66242
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn0306-5251
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/63690/2/Binde_et_al-2018-British_Journal_of_Clinical_Pharmacology.pdf
dc.type.versionAcceptedVersion


Files in this item

Appears in the following Collection

Hide metadata